Senseonics Expands Eversense 365 CGM to Europe with CE Mark Approval
Event summary
- Senseonics received CE Mark approval for Eversense 365, the world’s first 365-day continuous glucose monitor (CGM).
- The approval expands Senseonics’ addressable market by over 30 million diabetes patients in the EU.
- Eversense 365 is already FDA-approved and launched in the US in October 2024.
- Senseonics plans to launch Eversense 365 in Germany, Italy, Spain, and Sweden in 2026.
- The company is advancing partnership discussions with insulin pump manufacturers for automated insulin delivery (AID) systems.
The big picture
Senseonics’ CE Mark approval for Eversense 365 marks a significant step in its global expansion strategy, positioning it as a leader in long-term implantable CGM technology. The approval comes at a time when the diabetes management market is increasingly shifting toward integrated, automated solutions, with Senseonics aiming to capitalize on this trend through strategic partnerships and regulatory milestones.
What we're watching
- Market Penetration
- The pace at which Senseonics can establish Eversense 365 in key European markets will determine its revenue growth trajectory.
- Partnership Dynamics
- Whether Senseonics can secure strategic partnerships with insulin pump manufacturers to integrate Eversense 365 into AID systems.
- Regulatory Execution
- How the completion of the Gemini trial in the second half of 2026 will impact Senseonics’ long-term commercial strategy.
Related topics